CD19-directed CAR T-cell therapy, CD22 CAR T, Large B-cell lymphoma, Matthew J. Frank, NCT04088890
High CR rates are overcome by CD22-directed CAR T-Cell therapy against CD19 relapse in LBCL
In February 2023, a phase 1 trial at a single institution found that it was safe and possible for people with heavily pretreated large B-cell lymphoma (LBCL) to use CD22-directed chimeric antigen receptor (CAR) T-cell therapy aft..
ASTCT, CIBMTR, Large B-cell lymphoma, Matthew Frank, Miltenyi Biotec, Stanford University
Novel treatment target for lymphoma patients who relapse after CAR-T therapy
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Breyanzi, Juno Therapeutics, Large B-cell lymphoma, LBCL, TRANSFORM
Lisocabtagene maraleucel is approved by FDA for second-line treatment of large B-cell lymphoma
July 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been approved by the Food and Drug Administration for adult patients with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoi..
Carteyva, JW Therapeutics, Large B-cell lymphoma, lymphoma, NMPA, relmacabtagene autoleucel
JW Therapeutics’ IND is cleared by China NMPA for CAR T-Cell therapy in large B-Cell lymphoma
China's National Medical Products Administration (NMPA) has approved JW Therapeutics' investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in people with second-line large B-c..
ADC Therapeutics SA, alkylating agent conjugate, CD19-directed antibody, diffuse large B-cell lymphoma, DLBCL, high-grade B-cell lymphoma, Large B-cell lymphoma, Loncastuximab tesirine-lpyl, Zynlonta
The FDA has granted loncastuximab tesirine-lpyl accelerated approval for large B-cell lymphoma
August 2021: The FDA granted loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, accelerated approval for adult patients with relapsed or refractory large B-cell ly..